Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharacokinetic study in dogs.
To develop a HPLC-MS method of determining ginsenoside Rh2 in dog plasma based on solid-phase extraction for pharmacokinetic studies. Six dogs were randomly assigned to two groups, either given 0.1 mg/kg dose intravenously or 1 mg/kg dose through oral gavage. Analysis using high performance liquid chromatography (HPLC) with ODS column, followed by detection with electrospray ionization(ESI) mass spectrometry(MS) in negative ion mode with 500 microM ammonium chloride in the mobile phase. The assays were validated over the concentration range of 2.0-1250.0 ng/ml in dog plasma. The intra- and inter- day precision were less than 10% in terms of RSD. The overall recovery was more than 80%. The validated assay was suitable for pharmacokinetic studies of ginsenoside Rh2 and the observed oral bioavailabilities of Rh2 were 17.6% and 24.8% for male and female dogs respectively.
Xie
Hai-Tang
HT
Key laboratory of pharmacokinetics, China Pharmaceutical University, Nanjing, Jiangsu.
Wang
Guang-Ji
GJ
Lv
Hua
H
Sun
Rui Wang Jian-Guo
RW
Jiang
Xi-Ling
XL
Li
Hao
H
Wang
Wei
W
Huang
Chen-Rong
CR
Xu
Mei-Juan
MJ
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000032:analysis* / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D036145:Ginsenosides / Q000032:analysis* / Q000493:pharmacokinetics*; D013058:Mass Spectrometry; D012680:Sensitivity and Specificity
D000972:Antineoplastic Agents, Phytogenic; D036145:Ginsenosides; C055305:ginsenoside Rh2